Ncardia is a human iPSC technology company that operates worldwide with facilities, offices and staff throughout Europe and North America. We work with biopharmaceutical companies in drug discovery and cell therapy worldwide, to leverage the power of stem cell technologies in the development of novel therapies of multiple modalities at any stage of development.
Over the past 10 years, we have built the expertise and infrastructure required to differentiate, manufacture and characterize high-quality iPSC-derived cell and disease models. We can facilitate the process of disease modeling and high-throughput screening to accelerate drug discovery. In addition, our deep knowledge of and experience in cell biology and large-scale manufacturing capabilities enable the development of robust iPSC-based allogenic cell therapies in multiple therapeutic areas.
We listen to our customer’s project plans, questions and challenges, and co-develop human iPSC-based solutions that fit their specifications.
Explore our website to learn more www.ncardia.com.
Over the past 10 years, we have built the expertise and infrastructure required to differentiate, manufacture and characterize high-quality iPSC-derived cell and disease models. We can facilitate the process of disease modeling and high-throughput screening to accelerate drug discovery. In addition, our deep knowledge of and experience in cell biology and large-scale manufacturing capabilities enable the development of robust iPSC-based allogenic cell therapies in multiple therapeutic areas.
We listen to our customer’s project plans, questions and challenges, and co-develop human iPSC-based solutions that fit their specifications.
Explore our website to learn more www.ncardia.com.
Location: Belgium, Hainaut, Gosselies
Employees: 51-200
Total raised: $72.38M
Founded date: 2011
Investors 2
| Date | Name | Website |
| - | Le Groupe ... | sriw.be |
| - | SFPIM | sfpim.be |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 16.11.2021 | - | $60M | - |
| 17.11.2017 | Series B | $12.38M | - |
Mentions in press and media 5
| Date | Title | Description |
| 19.11.2024 | Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study | Highlights: Positive preclinical results in human in vitro iPSC Motor Neuron models of Amyotrophic Lateral Sclerosis (ALS) Neurizon's lead drug NUZ-001 and its major active metabolite significantly and dose-dependently prevented the aggrega... |
| 21.11.2022 | Prepaire™ Announces Partnership With Ncardia To Accelerate Plans To Discover New Drugs & Repurpose Existing Libraries | Ncardia to develop and manufacture Induced Pluripotent Stem-Cell based solutions (iPSC) for Prepaire. DUBAI, UNITED ARAB EMIRATES, November 21, 2022 /EINPresswire.com/ -- Prepaire™ Labs, an Omics company, mining, mapping & navigating bi... |
| 16.11.2021 | Ncardia Secures $60+ Million to Enhance and Expand Leading iPSC Offerings | Ncardia, a leader in developing stem cell-based solutions for drug discovery and cell therapy, announced that it has secured more than $60 million in capital through a strategic partnership with Kiniciti, a U.S.-based investment platform fo... |
| 16.11.2021 | Casper turns painful even for some of its earliest startup investors | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Even if a startup takes a cut to its valuation, it’s completely possible that investors who took ... |
| 17.11.2017 | Ncardia Completed €10.5M Series B Financing | Ncardia, a Gosselies, Belgium-based drug discovery and development stem cell technology company, completed a €10.5m series B financing round. The round was led by Épimède, with participation from InnovationQuarter, SRIW, SambrInvest, Vesali... |